Hosted on MSN

BAX Q3 Deep Dive: Mixed Segment Results and Lowered Guidance Drive Market Reaction

Healthcare company Baxter International (NYSE:BAX) in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below ...
American Association of Individual Investors

Is Baxter International Inc. (BAX) Stock a Good Investment?

Learn more about Baxter International Inc.'s (BAX) stock grades for Value, Momentum, Growth and Estimate Revisions and ...
Forbes

Is Now The Time To Buy Baxter Stock?

Baxter stock (NYSE: BAX), a healthcare company, has seen its stock decline by 14% over the past month. This drop followed a disappointing earnings report where the company also reduced its full-year ...
Business Wire

BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES-- (BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the ...
Hosted on MSN

BAX Q2 Deep Dive: Margin Pressure and Product Headwinds Temper Near-Term Outlook

Healthcare company Baxter International (NYSE:BAX) in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter’s revenue guidance of $2.87 billion was less ...